Angie Meillier, RN, MS, CPPM, discusses the importance of shared decision making and patient understanding in breast cancer and throughout oncology.
Angie Meillier, RN, MS, CPPM, Manager of Clinical Programs at Allina Health, discusses the importance of shared decision making and patient understanding in breast cancer and throughout oncology.
Shared decision making is a concept that is especially important in preference-sensitive conditions, such as the choice between lumpectomy and mastectomy for patients with breast cancer. There are a number of other choices in breast cancer, as well as throughout oncology. By ensuring that a patient fully understands the options they have and the outcomes, more of the patient’s own values and preferences can be incorporated into the decisions.
Workflow, Educational Tools Improve Use of Silicone Film to Prevent Radiation Dermatitis
April 25th 2024Tools to educate oncology nurses and patients on the use of Mepitel film to prevent radiation dermatitis has improved the workflow around its introduction to patients with breast cancer, as well as its application and maintenance.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
Workflow, Educational Tools Improve Use of Silicone Film to Prevent Radiation Dermatitis
April 25th 2024Tools to educate oncology nurses and patients on the use of Mepitel film to prevent radiation dermatitis has improved the workflow around its introduction to patients with breast cancer, as well as its application and maintenance.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
Relapsed/Refractory Follicular Lymphoma May Respond to Loncastuximab Tesirine Plus Rituximab
Cilta-cel Demonstrates 99.4% ORR in Lenalidomide-Refractory Myeloma
Multidisciplinary Infrastructure Streamlines Cancer Care During Drug Shortages
Workflow, Educational Tools Improve Use of Silicone Film to Prevent Radiation Dermatitis
2 Commerce Drive
Cranbury, NJ 08512